Apitolisib(GDC-0980,RG7422) is a dual PI3K/mTOR inhibitor.GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.
仅供研究使用。 我们不向患者出售。
化学信息
名称 | Apitolisib(GDC-0980,RG7422) |
Iupac 化学名称 | (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one |
分子式 | C23H30N8O3S |
分子量 | 498.6 |
Smile | NC1=NC=C(C=N1)C=1N=C(C2=C(N1)C(=C(S2)CN2CCN(CC2)C([C@H](C)O)=O)C)N2CCOCC2 |
InChiKey | YOVVNQKCSKSHKT-HNNXBMFYSA-N |
InChi | InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1 |
Cas号 | 1032754-93-0 |
相关CAS号 | |
外观性状 | solid |
纯度 | >98% by HPLC |
存储 | 3 years -20ºCpowder |
可溶性 | Soluble in DMSO |
处理方式 | |
运输条件 | Shipped under ambient temperature |
海关编码 | |
Targets | |
Mechanism | |
Cell study | |
Animal study | |
Clinical study | |